Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01215786 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-Angle
Ocular Hypertension

Interventions

DRUG: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
DRUG: timolol ophthalmic solution 0.5%
DRUG: AGN-207281 vehicle ophthalmic solution (Placebo)

Sponsor

Allergan